12:22:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-28 Årsstämma 2024
2024-05-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2022-05-09 08:30:00

Ziccum’s Director of Development Anna Lönn has now been elected onto the Technical Activities Committee of the US National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), which will have its first meeting on May 23, 2022. NIIMBL, co-funded by the US Department of Commerce, funds and initiates a wide range of public-private research projects throughout the US.

Ziccum is one of a few European members invited to join NIIMBL, becoming a member in March 2021. NIIMBL is a public-private partnership that helps fund an ambitious range of research projects to accelerate biopharmaceutical innovation in manufacturing and supply. Members include industry, academic and government organizations within pharmaceutical manufacture and supply.

Anna Lönn, Ziccum’s Development Director has been elected to NIIMBL’s Technical Activities Committee (TAC) for the period 2022 - 2023. Anna, who joined Ziccum in September 2021 from TetraPak, has driven significant development throughout the company together with a highly skilled development team. Since September they have established the company’s expanded lab facilities and mRNA capabilities, and driven ahead its ambitious Quality by Design-led program of technological development. Fellow NIIMBL members on the TAC include representatives from noted vaccine developers, biologics companies working on viral vectors and viral vaccines, and academics from leading US universities within bioprocesses and pharmaceutics.

Ziccum Chairman Fredrik Sjövall: “The election of Anna really reflects her outstanding professionalism and expertise; she will bring fantastic qualities to fascinating work. We welcome the opportunities for networking and partnerships that TAC brings, and the possibilities for soft funding that can come through involvement with organizations like NIIMBL and CEPI (the Coalition for Epidemic Preparedness Innovation.) Our recent invitation from CEPI to submit an application for their soft-funded project on innovation in thermostable vaccines, plus our ongoing work with NIIMBL, are all good examples of the awareness and interest in the industry around our technology. We look forward to making a valuable contribution.”

READ MORE

  • Read more about NIIMBL here.
  • Read more about LaminarPace here.